Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open-label, phase 2 trial.

In 30 seconds

This multicenter, open-label, phase 2 trial evaluated the safety and efficacy of vimseltinib in adults with tenosynovial giant cell tumor (TGCT) not amenable to surgery. The study found that vimseltinib achieved best overall response rates of 64% in patients without prior anti-CSF1/CSF1R treatment and 37% in those with prior treatment, with most patients reporting improvements in physical function and pain.

Key findings

• Best overall response rates were 64% in cohort A and 37% in cohort B.
• Most treatment-emergent adverse events were grade 1/2.
• Patients reported meaningful improvements in active range of motion and physical function.

Why it matters

The findings suggest that vimseltinib is a promising treatment option for patients with TGCT who are not candidates for surgery, potentially improving their quality of life and functional outcomes.